Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M412317200 on March 11, 2005

J. Biol. Chem., Vol. 280, Issue 19, 19426-19435, May 13, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/19/19426    most recent
M412317200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, C.
Right arrow Articles by Klip, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, C.
Right arrow Articles by Klip, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Differential Contribution of Insulin Receptor Substrates 1 Versus 2 to Insulin Signaling and Glucose Uptake in L6 Myotubes*

Carol Huang{ddagger}§||, Ana C. P. Thirone{ddagger}||, Xudong Huang{ddagger}**, and Amira Klip{ddagger}{ddagger}{ddagger}

From the {ddagger}Program in Cell Biology, The Hospital for Sick Children, Toronto, Ontario M5G 1X8 and the §Institute of Medical Sciences, University of Toronto, Toronto, Ontario M5S 1A8, Canada

Received for publication, November 1, 2004 , and in revised form, March 8, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Insulin receptor substrates-1 and 2 (IRS-1 and IRS-2) are pivotal in relaying insulin signaling in insulin-responsive tissues such as muscle. However, the precise contribution of IRS-1 vis-à-vis IRS-2 in insulin-mediated metabolic and mitogenic responses has not been compared directly in differentiated muscle cells. This study aimed to determine the relative contribution of IRS-1 versus IRS-2 in these responses, using small interfering RNA (siRNA)-mediated specific gene silencing. In L6 myotubes, transfection of siRNA targeted specifically against IRS-1 (siIRS-1) or IRS-2 (siIRS-2) reduced the cognate protein expression by 70–75%. Insulin-induced ERK phosphorylation was much more sensitive to IRS-2 than IRS-1 ablation, whereas p38MAPK phosphorylation was reduced by 43 or 62% in myotubes treated with siIRS-1 or siIRS-2, respectively. Insulin-induced Akt1 and Akt2 phosphorylation was reduced in myotubes treated with siIRS-1, but only Akt2 phosphorylation was reduced in myotubes treated with siIRS-2. In contrast, siIRS-1 treatment caused a marked reduction in insulin-induced actin remodeling, glucose uptake, and GLUT4 translocation, and siIRS-2 was without effect on these responses. Notably, combined siIRS-1 and siIRS-2, although reducing each IRS by around 75%, caused no further drop in glucose uptake than that achieved with siIRS-1 alone, but abolished p38MAPK phosphorylation. We conclude that insulin-stimulated Akt1 phosphorylation, actin remodeling, GLUT4 translocation, and glucose uptake are regulated mainly by IRS-1, whereas IRS-2 contributes selectively to ERK signaling, and Akt2 and p38MAPK lie downstream of both IRS in muscle cells.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Insulin receptor substrates (IRSs)1 mediate diverse metabolic and mitogenic effects of insulin, and dysregulation of IRS expression and activation has been observed in both insulin resistance and diabetes (1–5). To date, six IRS proteins have been identified, but only IRS-1 and IRS-2 are thought to participate in regulation of glucose homeostasis (6–9). Although IRS-1 and 2 have substantial amino acid similarity (10), there are significant structural differences between them. IRS-2 interacts with the insulin receptor via a phosphotyrosine-binding domain as well as a central domain located between amino acid 591 and 733 which is absent from IRS-1 (11, 12). Furthermore, IRS-1 and IRS-2 differ in their time course of insulin-stimulated tyrosine phosphorylation (13, 14), interaction with the MAPK pathway (15), and intracellular localization (14).

Defining the exact roles of IRS isoforms in insulin-stimulated glucose uptake is not without controversy. In rat adipocytes, overexpression of human IRS-1 increased, whereas elimination of IRS-1 via antisense ribozyme reduced, insulin-stimulated GLUT4 translocation (16). However, other studies observed intact insulin-stimulated GLUT4 translocation when the interaction between insulin receptor and IRS was blocked, although insulin-mediated DNA synthesis and cell growth were reduced (17–19). Furthermore, IRS-1-null mice, although significantly growth-retarded, do not develop overt diabetes, suggesting that IRS-1 plays a more important role in mediating the mitogenic rather than the metabolic effects of insulin (20, 21). When the insulin response of individual tissues was examined, however, phosphatidylinositol 3-kinase activation and glucose uptake were reduced in muscle (22) and adipocytes (23), although the liver preserved normal phosphatidylinositol 3-kinase and MAPK activities (22). These latter results suggested that IRS-1 participates in insulin-stimulated glucose uptake in muscle and adipocytes, whereas in liver, other IRS protein(s) is responsible for insulin action.

IRS-2 was identified as the alternative insulin receptor substrate in the liver and muscle of the IRS-1-null mice (10, 24). Overexpression of IRS-2 in rat adipocytes increased GLUT4 translocation (25), whereas brown adipocytes isolated from IRS-2-null mice showed reduced insulin-stimulated glucose transport and GLUT4 translocation (26). Interestingly, when stimulated with insulin ex vivo, isolated soleus muscles from the IRS-2-null and wild type mice had similar glucose uptake response, albeit with a lower basal glucose transport rate, suggesting that IRS-2 may not be required for insulin-stimulated glucose transport in skeletal muscle (27). Of note, the total GLUT4 expression was decreased in the IRS-2-null mice, yet the insulin-stimulated glucose uptake response was not diminished. A later in vivo study using the hyperinsulinemic-euglycemic clamp, however, showed that although IRS-1 is the major regulator of glucose transport in muscle, IRS-2 also participates in glucose metabolism in muscle, fat, and liver (28). These studies are summarized in Table I. Taken together, studies to date support the requirement of IRS-1 in insulin-stimulated glucose metabolism in muscle, whereas the precise role of IRS-2 in this tissue requires further investigation.


View this table:
[in this window]
[in a new window]
  		TABLE I
Relationship between IRS protein expression level and insulin-stimulated glucose uptake and GLUT4 translocation in muscle and adipose tissues

 
Insulin elicits both mitogenic and metabolic responses, which include activation of the MAPK pathway and gene expression, as well as increasing Akt activity and inducing actin remodeling. The latter two participate in the regulation of insulin-stimulated GLUT4 translocation and glucose uptake (29–33). The objective of this study was to determine the relative contribution of IRS-1 versus IRS-2 in these responses, using siRNA-mediated specific gene silencing. The transient nature of siRNA-mediated protein reduction minimizes the possibility of compensatory up-regulation of other proteins that may mask the biological consequences of eliminating IRS-1/2. In addition, we made use of the L6-GLUT4myc rat skeletal muscle cell line that stably expresses a myc-tagged GLUT4, where the expression of the GLUT4myc is constant and resistant to manipulations that may affect expression of other proteins (34). This allows us to determine the importance of IRS-1/2 in the regulation of glucose uptake and GLUT4 translocation without the confounding factor of altered GLUT4 expression (34–36), as was observed in the skeletal muscle of IRS-2-null mice.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Phospho-specific antibodies to p38MAPK (dual phosphorylated Thr180 and Tyr182), Akt (Thr308 and Ser473), and ERK were purchased from Cell Signaling (Beverly, MA). Polyclonal anti-phosphotyrosine, anti-IRS-1, anti-IRS-2, and anti-Rat-Akt2 (immunoaffinity-purified sheep IgG) antibodies (for immunoprecipitation, immunoblotting, and immunofluorescence experiments) were from Upstate Biotechnology (Lake Placid, NY). Dr. Morris White generously provided rabbit anti-IRS-1 and anti-IRS-2 antibodies used for immunoprecipitation. Polyclonal anti-myc (A14) and anti-Akt1 (D17-goat IgG) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). SiRNAs targeted against IRS-1 (siIRS-1), IRS-2 (siIRS-2), and nonrelevant control (siNR) were purchased from Dharmacon (Lafayette, CO). The sequence of the IRS-1 siRNA used was AAC AAG ACA GCU GGU ACC AGG, and the nonrelevant control X was AUU CUA UCA CUA GCG UGA CUU. The nonrelevant control siRNA sequence was screened against the expressed sequence tag gene bank data base and had no homology to the vertebrate genome. IRS-2 Smartpool® siRNA was designed by and purchased from Dharmacon. Fetal bovine serum (FBS) and calf serum were obtained from Invitrogen. Human insulin (Humulin R) was purchased from Eli Lilly Canada, Inc. (Toronto, ON). Cytochalasin B, mercuric chloride, D-glucose, 2-deoxy-D-glucose, all protease inhibitors, and o-phenylenediamine dihydrochloride (OPD reagent) were from Sigma. 2-Deoxy-D-[1,2-3H]glucose was purchased from PerkinElmer Life Sciences.

Tissue Culture—L6 muscle cells stably expressing myc-tagged GLUT4 (L6-GLUT4myc cells) were described previously (34, 36–38). GLUT4myc myoblasts were differentiated into myotubes in {alpha}-MEM supplemented with 2% FBS, 1% antibiotics/antimycotics over 7 days. Myotube cultures contained less than 20% mononucleated cells. Cultures were deprived of serum for 5 h prior to stimulation with insulin.

Transfection of siRNA—L6 myotubes were transfected with siIRS-1 or siNR using Oligofectamine Reagent from Invitrogen as per the manufacturer's instruction, with minor modifications. The differentiation medium was changed to antibiotic-free growth medium on day 3 of myotube differentiation, and on day 4, 400 nM siRNA was transfected using Oligofectamine in serum-free {alpha}-MEM. 4 h after transfection, {alpha}-MEM containing 6% FBS was added to each well to a final concentration of 2% FBS (v/v). The siRNA duplex was never removed from the medium when using the Oligofectamine transfection protocol. In some experiments, siRNA to IRS-1 was also introduced to cells using the calcium phosphate protocol required for effective IRS-2 gene silencing as described below, and equivalent IRS-1 knock-downs were achieved with either Oligofectamine or calcium phosphate-based transfection reagent, as detailed under "Results."

L6 myoblasts were transfected with siIRS-2 using a calcium phosphate-based transfection reagent (CellPhect transfection kit, Amersham Biosciences), according to the manufacturer's instruction. Briefly, cells were seeded at 30% confluence in {alpha}-MEM supplemented with 10% FBS without antibiotics/antimycotics. On day 2, myoblasts were transfected with 50 nM siRNA, and the medium was changed 12–14 h later to {alpha}-MEM supplemented with 2% FBS with 1% antibiotics/antimycotics. Cells were transfected again on day 5 with 100 nM siRNA. SiRNA transfection had no deleterious effects on either cell viability or fusion of myoblasts to form myotubes.

Double elimination of IRS-1 and IRS-2 was achieved using the calcium phosphate transfection protocol described above.

Fluorescence Microscopy—L6-GLUT4myc myotubes grown on 25-mm-diameter glass coverslips were deprived of serum for 5 h and treated with 0–100 nM insulin for 10 min at 37 °C. Myotubes were fixed with paraformaldehyde immediately at 4 °C after insulin stimulation and permeabilized in 0.1% (v/v) Triton X-100 for 3 min to preserve actin morphology. Actin filaments were labeled with rhodamine-coupled phalloidin, and immunostaining of IRS-1 or IRS-2 in fixed and permeabilized myotubes was carried out as described previously (39). Primary antibody (IRS-1 and IRS-2 purchased from Upstate Biotechnology) was used at 1:500 dilution. Cells were examined with a Zeiss LSM 510 laser scanning confocal microscope. Acquisition parameters were adjusted to exclude saturation of the pixels. For quantification, such parameters were kept constant among the various conditions compared.

Determination of 2-Deoxyglucose Uptake—2-Deoxyglucose uptake measurements were carried out as described previously (36) for 5 min in HEPES-buffered saline containing 10 µM 2-[3H]deoxyglucose (0.5 µCi/ml) in the absence of insulin. Glucose transport was stopped with ice-cold 0.9% NaCl containing 1 mM HgCl2. Nonspecific uptake was determined in the presence of 10 µM cytochalasin B and subtracted from all experimental values.

Immunoprecipitation of IRS-1 and IRS-2—L6 myotubes were stimulated with insulin for 5 min (for IRS-1 studies) or 3 min (for IRS-2 studies), times at which phosphorylation of each isoform peaks (13). IRS-1 and IRS-2 were immunoprecipitated from L6 myotubes as described previously (34, 40). Briefly, 500 µg or 1 mg of protein of whole cell lysates in Triton X-100 were incubated with IRS-1- or IRS-2-specific antibodies at 4 °C overnight under constant rotation, and the antibody-antigen complex was pulled down by protein A/G-Sepharose beads. The pelleted protein was resolved by 7.5% SDS-PAGE, and tyrosine phosphorylation of IRS-1 or IRS-2 was detected by immunoblotting with monoclonal anti-phosphotyrosine antibody.

Immunoprecipitation of Akt1 and Akt2—L6 myotubes were stimulated with 100 nM insulin for 10 min. We have determined previously that 10 min of stimulation yields maximal phosphorylation of Akt in these cells (44). Immunoprecipitation of Akt1 and Akt2 was performed from 200 µg of cell lysates in Triton X-100 containing phosphatase and protease inhibitors (44). The antibody-antigen complex was pulled down by protein A/G-Sepharose beads. The pelleted proteins were resolved by 10% SDS-PAGE, and serine and threonine phosphorylation of Akt1 or Akt2 was detected by immunoblotting using anti-phospho-Akt-Ser473 or -Thr308 antibody.

Reverse Transcription-PCR of Insulin Receptor Isoforms—Isolation of total RNA and reverse transcription-PCR of insulin receptor from L6 myotubes were performed as described previously (41). The primers used to amplify insulin receptor were: CAT TCA GGA AGA CCT TCG AGG and TCT GGG GAG TCC TGA TTG CAT.

Measurement of GLUT4myc Translocation in L6 Myotubes—Cell surface myc-tagged GLUT4 was quantified by an antibody-coupled colorimetric assay as validated previously (35). Briefly, after a 20-min incubation with insulin at indicated concentrations, confluent myotubes were exposed to anti-myc antibody (1:100) for 60 min, fixed with 4% paraformaldehyde for 10 min, and then incubated with peroxidase-conjugated goat anti-rabbit IgG (1:750) for 45 min, all at 4 °C. Cells were washed six times with phosphate-buffered saline, and 1 ml of OPD reagent was added for 30 min at room temperature. The reaction was stopped with 0.25 ml of 3 N HCl. The supernatant was collected, and absorbance was measured at 492 nm. Nonspecific IgG binding, as measured by a peroxidase-conjugated anti-rabbit IgG and omitting the primary antibody, was subtracted from all experimental values.

Detection of Cellular Protein Expression and Protein Phosphorylation—Whole cell lysates were made from myotubes after incubation with insulin (0–100 nM) for 10 min (as described previously (42)). We have determined previously that 10 min of stimulation yields maximal phosphorylation of Akt and p38MAPK and is also the time shown previously to yield robust ERK phosphorylation in these cells (43). 40 µg of lysates was resolved by SDS-PAGE and transferred onto polyvinylidene difluoride filters, which were incubated with primary antibodies overnight at 4 °C under constant agitation (dilutions: polyclonal anti-IRS-1 or anti-IRS-2, 1:1,000; anti-Akt, anti-ERK, and anti-p38MAPK, 1:500–1:1,000; anti-phospho-Akt-Ser473 or -Thr308, antiphospho-ERK, and anti-phospho-p38MAPK, 1:500), followed by a 1-h incubation with horseradish peroxidase-conjugated secondary antibody (1:15,000 goat anti-rabbit antibody, 1:7,500 sheep anti-mouse antibody). Protein was visualized by the enhanced chemiluminescence method and scanned within the linear range using ImageJ software.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Insulin-stimulated Tyrosine Phosphorylation of IRS-2 Is More Insulin-sensitive Than That of IRS-1—We first compared the insulin sensitivity of IRS-1 tyrosine phosphorylation with that of IRS-2. L6-GLUT4myc myotubes were incubated with increasing concentrations of insulin (0.5–100 nM) for 3–5 min, and the results were expressed as a percentage of the response observed at 100 nM insulin. As shown in Fig. 1, insulin-stimulated tyrosine phosphorylation of IRS-2 is more sensitive at low concentrations of insulin than is IRS-1, with an EC50 of 0.5 nM for IRS-2 versus 5–8 nM for IRS-1. A similar difference of insulin sensitivity of IRS-1 and IRS-2 tyrosine phosphorylation was observed in myoblasts (results not shown). Hence, any possible presence of myoblasts in the cultures would be unlikely to be responsible for the marked difference in insulin-sensitivity of IRS-1 and IRS-2.

Akt Phosphorylation Is More Insulin-sensitive Than Phosphorylation of p38MAPK or ERK—Akt, p38MAPK, and ERK have been shown to regulate GLUT4 translocation, glucose uptake, and mitogenic responses, respectively. However, with the exception of Akt, it is unclear whether p38MAPK and ERK are directly downstream of IRS in the insulin signaling pathway. Therefore, we next examined the insulin sensitivities of these enzymes compared with those of IRS-1 and IRS-2. L6 myotubes were treated with increasing concentrations of insulin (0.5–100 nM) for 10 min, and whole cell lysates were prepared. In response to insulin, Akt is phosphorylated at threonine 308 and serine 473, p38MAPK at threonine 180 and tyrosine 182, and ERK at threonine 202 and tyrosine 204. As shown in Fig. 2, insulin-mediated serine phosphorylation of Akt was detected at a lower concentration of insulin than phosphorylation of p38MAPK or ERK, beginning at 0.5, 2, and 5 nM insulin, respectively. Again, the differential sensitivity of these signaling molecules to insulin is unlikely to arise from any residual presence of myoblasts in the culture because, as reported previously, Akt activation and expression (36) and p38MAPK expression (44) did not differ during myogenic differentiation of the culture.

Insulin-induced Actin Structures Are Observed at a Low Concentration of Insulin and Colocalize with IRS-1 but Not IRS-2—One of the earliest responses to insulin is the rearrangement of actin filaments into a cortical mesh. This phenomenon occurs in muscle cells (29, 31, 39, 45), adipocytes (46, 47), and skeletal muscle (48). Actin remodeling is deemed necessary for GLUT4 translocation, but its insulin dose sensitivity was not known. L6 myotubes were incubated with 0.5–100 nM insulin for 10 min and then stained F-actin with rhodamine-phalloidin. Insulin-induced cortical actin structures were observed at 0.5 nM insulin. The remodeled actin structures, clearly visualized on the dorsal plane of the myotubes, became larger and more distinctive with increasing concentrations of the hormone (Fig. 3).



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 1.
Insulin-stimulated tyrosine phosphorylation of IRS-2 is more insulin-sensitive than that of IRS-1. Myotubes were grown and differentiated as described under "Experimental Procedures." 5 h prior to experiments, cells were deprived of serum and then stimulated with insulin at the indicated concentrations for 3 (IRS-2) or 5 (IRS-1) min. Cells were lysed, and IRS-1 or IRS-2 was immunoprecipitated (IP) from 500 or 1,000 µg of protein, respectively. Tyrosine phosphorylation of IRS-1 or IRS-2 was determined by immunoblotting (IB), and results are expressed as a percentage of maximal insulin response, setting the amount of tyrosine phosphorylation obtained with 100 nM insulin as 100%. A representative blot is shown in A. The mean ± S.E. of four or five independent experiments is summarized in B.*, p < 0.05 compared with tyrosine phosphorylation of IRS-1 at the corresponding insulin concentrations.

 
IRS-1 and IRS-2 Participate in Insulin-stimulated Phosphorylation of Akt—The results so far revealed that a low insulin concentration (0.5 nM) stimulated tyrosine phosphorylation of IRS-2, Akt phosphorylation, and actin remodeling, whereas a higher concentration of insulin (≥5 nM) was required to obtain appreciable IRS-1, p38MAPK, and ERK phosphorylation. It is unknown whether these correlations reflect differential regulation of Akt, p38MAPK, ERK activation, and actin remodeling by IRS-2 versus IRS-1. Therefore, we induced gene-specific silencing in L6 myotubes, using siIRS-1 and siIRS-2, to determine their relative contribution in insulin action.

Using siIRS-1 we achieved a 75% reduction in IRS-1 protein expression with little reduction in IRS-2 expression; conversely, siIRS-2 reduced IRS-2 protein by 70% with no effect on IRS-1 expression (Fig. 4A). SiRNA-treated L6 myotubes were incubated with submaximal (5 nM) or maximal (100 nM) concentrations of insulin for 10 min, and Akt phosphorylation at threonine 308 and serine 473 was determined. The insulin-stimulated (100 nM, 10 min) increase in Akt phosphorylation above basal of siNR-treated cells was designated as the maximal response and expressed as 100%. Akt phosphorylation above basal observed with any other conditions was expressed as a percentage of this (maximal) response. The 75% depletion of IRS-1 or the 70% depletion of IRS-2 resulted in significant reductions in Akt phosphorylation at both threonine 308 and serine 473. At the maximal (100 nM) insulin dose, insulin-mediated Akt phosphorylation (Ser473) dropped to 58 ± 12% in siIRS-1-treated cells and to 48 ± 7% in siIRS-2-treated cells, relative to the response in siNR-treated cells (Fig. 4B). A similar drop was observed at the submaximal dose of insulin (5 nM): Akt phosphorylation values were and 15 ± 8% or 9 ± 5% of the maximal value in cells treated with siIRS-1 or siIRS-2, respectively, compared with about 55% of maximum in siNR-treated cells. Concomitant reductions in Akt phosphorylation on threonine 308 were observed (not shown). Of note, siRNA-mediated reduction of IRS-1 and IRS-2 had no impact on Akt protein expression (Fig. 4B).



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 2.
Akt is more insulin-sensitive than p38MAPK or ERK. Myotubes were serum deprived for 5 h prior to incubation with indicated concentrations of insulin for 10 min, and total cell lysates were prepared in Laemmli sample buffer. 40 µg of protein was immunoblotted for phospho-Akt (Ser473), phospho-p38MAPK (Thr180 and Tyr182), and phospho-ERK (Thr183 and Tyr185). Results are expressed as a percentage of maximal insulin response, setting the amount of phosphorylation observed at 100 nM insulin as 100%, after subtracting the basal level of phosphorylation. Representative immunoblots are shown in A. Results of seven or eight independent experiments are summarized in B. *, p < 0.05 compared with p38MAPK or ERK phosphorylation at the corresponding insulin concentrations.

 



View larger version (100K):
[in this window]
[in a new window]
  		FIG. 3.
Insulin-induced cortical actin structures are observed at low concentrations of insulin. Myotubes grown on coverslips were serum deprived for 5 h prior to stimulation with 0–100 nM insulin for 10 min at 37 °C followed by fixation and permeabilization. Filamentous actin was stained with rhodamine-conjugated phalloidin, and images were obtained by confocal microscopy. The images were acquired from the dorsal surfaces of the myotubes where F-actin reorganizes into mesh-like structures in response to insulin (39). Representative images of three independent experiments are shown.

 
Differential Effects of IRS-1 and IRS-2 on Akt Isoforms—The Akt phosphorylation shown in Fig. 4 reflects the net behavior of all Akt isoforms. To examine the contribution of IRS-1 and IRS-2 to the major Akt isoforms 1 and 2, siRNA-treated L6 myotubes were incubated without or with 100 nM insulin for 10 min, and Akt1 or Akt2 was individually immunoprecipitated and probed with anti-phospho-Akt antibodies. Fig. 5 shows that reduction of IRS-1 expression led to a blunted insulin-stimulated serine phosphorylation of Akt1 (66 ± 11% versus siNR-treated myotubes) and of Akt2 (55 ± 5% versus siNR-treated myotubes). In contrast, reduction of IRS-2 expression affected only Akt2 phosphorylation (62 ± 8% versus siNR-treated myotubes). Similar observations were made for threonine phosphorylation in all cases (results not shown).

IRS-1 and IRS-2 Differentially Mediate Insulin-stimulated Phosphorylation of p38MAPK and ERK—Insulin causes activation of ERK and p38MAPK in several cell lines. We therefore examined the contribution of IRS-1 and IRS-2 in relaying the insulin signal to these MAPK pathways. In cells treated with siIRS-1, insulin-stimulated phosphorylation of p38MAPK at submaximal (5 nM) and maximal (100 nM) insulin concentrations was 17 ± 7% and 57 ± 2% of that in cells treated with siNR and stimulated with 100 nM insulin (for 10 min). In cells treated with siIRS-2, insulin-stimulated phosphorylation of p38MAPK at 5 or 100 nM was 25 ± 10% and 38 ± 5% of the maximal response in siNR-treated cells (Fig. 6A). Again, siIRS-1 and siIRS-2 had no effect on p38MAPK protein expression (Fig. 6A).

Interestingly, and in contrast to p38MAPK, IRS-2 appeared to contribute more significantly than IRS-1 to the insulin-stimulated activation of ERK (Fig. 6B). ERK was minimally phosphorylated at 5 nM insulin, whether in cells transfected with siIRS-1, siIRS-2, or siNR. However, at the maximal insulin dose (100 nM), ERK phosphorylation in cells transfected with siIRS-1 was 76 ± 0.6% of the control (siNR-transfected) cells, whereas ERK phosphorylation in siIRS-2-transfected cells was only 15 ± 5% of the controls (Fig. 6B).

IRS-1 but Not IRS-2 Leads to Insulin-stimulated Glucose Uptake and GLUT4 Translocation—To our surprise, a 70% reduction in IRS-2 had no effect on insulin-stimulated glucose uptake or GLUT4 translocation at either submaximal (5 nM) or maximal (100 nM) insulin concentrations (Fig. 7B). In contrast, siRNA-mediated reduction of IRS-1 by 75% significantly reduced insulin-stimulated glucose uptake and GLUT4 translocation (Fig. 7A). Compared with cells transfected with siNR, siIRS-1-treated cells experienced 61 and 51% reductions in insulin-stimulated glucose uptake at submaximal (5 nM) and maximal (100 nM) insulin concentrations, respectively (Fig. 7A). Similar reductions were observed in insulin-stimulated translocation of GLUT4 to cell surface (Fig. 7A).



View larger version (41K):
[in this window]
[in a new window]
  		FIG. 4.
Both IRS-1 and IRS-2 participate in insulin-stimulated Akt phosphorylation. Myotubes were transfected with siRNA targeted specifically against IRS-1, IRS-2, or siNR as described under "Experimental Procedures." Cells were depleted of serum and insulin for 5 h followed by a 10-min incubation with insulin (0, 5, or 100 nM). Total cell lysates were prepared in Laemmli sample buffer, and 40 µg of protein was immunoblotted (IB) for IRS-1 (A, upper panel), IRS-2 (A, lower panel), total Akt (B and C), and), or phospho-Ser473-Akt (B). The reduction in IRS-1 or IRS-2 by the specific siRNAs is expressed as a percentage of the amount of protein present in cells treated with siNR (A). Insulin-stimulated Akt phosphorylation is expressed as a percentage of the response obtained with 100 nM insulin in cells transfected with siNR (B and C), and the results represent the mean ± S.E. of five to seven independent experiments. ***, p < 0.001; **, p < 0.01; *, p < 0.05 versus cells transfected with siNR at the corresponding insulin concentration. White bars, siNR; striped bars, siIRS-1; black bars, siIRS-2.

 
Unlike the insulin response, basal glucose uptake was not affected by reduction in either IRS-1 or IRS-2, as follows. In the experiments analyzing the effect of siIRS-1, basal glucose uptake was 26 pmol/min/mg of protein in the control siNR-treated myotubes and 30 pmol/min/mg of protein in siIRS-1-treated myotubes measured in parallel. In the siIRS-2 experiments, basal glucose uptake was 15 pmol/min/mg of protein in the control siNR-treated myotubes and 16.5 pmol/min/mg of protein in siIRS-2 myotubes. Likewise, the basal amount of cell surface GLUT4myc was not significantly affected by siIRS-1 or siIRS-2 (for siIRS-1, surface GLUT4myc was 1.23 ± 0.04 relative to siNR, which was assigned a value of 1; for siIRS-2, surface GLUT4myc was 1.06 ± 0.1 relative to siNR).

Consistent with the participation of actin remodeling in insulin-stimulated GLUT4 translocation, a much diminished insulin-induced cortical actin structure was apparent in myotubes treated with siRNA against IRS-1 (Fig. 8A) but not in myotubes treated with siIRS-2 (Fig. 8B). Consistent with these observations, IRS-1 colocalized with the insulin-stimulated actin mesh (39), but no significant colocalization between actin structures and IRS-2 was noted (data not shown).

It is possible that the drop in IRS-2 expression had no effect on insulin-stimulated glucose uptake because IRS-1 substituted for IRS-2 in this metabolic function. To test this possibility, L6 cells were transfected with siRNAs targeted against both IRS-1 and IRS-2. This strategy (siIRS-1/2) achieved 73 and 79% elimination of IRS-1 and IRS-2 protein, respectively, but insulin-stimulated glucose uptake was not further reduced compared with cells transfected with only siIRS-1 (Fig. 9A).

Insulin-stimulated phosphorylation of Akt (Ser473) was reduced to a similar extent in cells transfected with siIRS-1, siIRS-2, or siIRS-1/2 (Fig. 9B, left panel). Thr308 phosphorylation was somewhat lower in cells transfected with siIRS-2 or siIRS-1/2 compared with siIRS-1-transfected cells, but the difference was not statistically significant (Fig. 9B, right panel).



View larger version (30K):
[in this window]
[in a new window]
  		FIG. 5.
Akt1 phosphorylation is reduced by IRS-1 but not IRS-2 gene silencing. Cells were treated with siRNAs and incubated without or with insulin (100 nM) as in Fig. 4, then Akt1 (upper panel) or Akt2 (lower panel) was selectively immunoprecipitated (IP) from cell lysates as described under "Experimental Procedures." Insulin-stimulated Akt isoform phosphorylation is expressed as a percentage of the response obtained with 100 nM insulin in cells transfected with nonrelevant siRNA, and the results represent the mean ± S.E. of three to five independent experiments. ***, p < 0.001; **, p < 0.01; *, p < 0.05 versus cells transfected with siNR at the corresponding insulin concentration. White bars, siNR; striped bars, siIRS-1; black bars, siIRS-2; IB, immunoblotting.

 
Unlike the residual Akt phosphorylation seen with siIRS-1/2-treated cells, insulin-mediated phosphorylation of p38MAPK was essentially abolished in cells transfected with siIRS-1/2 (Fig. 9C). Finally, as expected, the ERK response was eliminated in cells treated with siIRS-1/2 as was with siIRS-2 (Fig. 9D).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Since the identification of IRS-1 and IRS-2, studies in various biological systems, including IRS-1 and IRS-2 knock-out mice, have supported a pivotal role for IRS isoforms in the metabolic and mitogenic effects of insulin (7, 8). However, there are conflicting reports on the precise role of IRSs in insulin-stimulated GLUT4 translocation and glucose transport (16, 18, 26, 28), and to our knowledge, the relative contribution of IRS-1 vis-à-vis IRS-2 in insulin-stimulated glucose uptake and GLUT4 translocation, as well as in Akt and MAPK signaling, has not been compared directly in muscle cells. In this study, we made use of siRNA-mediated gene silencing to knock down specifically IRS-1 or IRS-2 in L6 myotubes. We found that reducing endogenous IRS-1 protein by 70% (without reduction in IRS-2) abated by 55% the insulin-stimulated GLUT4 translocation to the cell surface, with a corresponding drop in insulin-stimulated glucose uptake. Interestingly, reducing endogenous IRS-2 expression by 75% had no effect on insulin-stimulated glucose uptake or GLUT4 translocation (see Table II).


View this table:
[in this window]
[in a new window]
  		TABLE II
Reductions in signaling molecules in response to siIRS-1 and siIRS-2 and suggested implications for signal transduction downstream of IRS-1 and IRS-1 The data in the table are expressed as percentage drop in insulin-stimulated response in comparison to respective values in siNR-treated cells. ND, not done.

 
As shown in Fig. 1, insulin-stimulated tyrosine phosphorylation of IRS-2 is more insulin-sensitive than that of IRS-1, and similar but less pronounced differences have been reported earlier (13, 49). Because tyrosine phosphorylation of IRS by insulin requires recruitment to the insulin receptor, this differential insulin sensitivity could potentially be secondary to differential recruitment of IRS-1 and IRS-2 by the two spliced isoforms of the insulin receptor, A or B (50–52). However, by reverse transcription-PCR amplification of mRNA isolated from L6-GLUT4myc myoblasts and myotubes, only isoform A of the insulin receptor was transcribed (data not shown). Therefore, the mechanism for the differential insulin sensitivities of IRS-1 versus IRS-2 tyrosine phosphorylation most likely resides in differences between the two IRS isoforms.

Indeed, although IRS-1 and 2 share between 75% (N-terminal region) and 35% (C-terminal region) amino acid identity, they display significant differences that may contribute to their functional divergence. First, IRS-2 interacts with the insulin receptor and insulin-like growth factor I (IGF-I) receptors via its phosphotyrosine-binding domain as well as a central domain located between amino acids 591 and 733 which is absent from IRS-1. This interaction requires a tyrosine-phosphorylated receptor but it is independent of the NPX(p)Y (Tyr960) site (11, 12). The presence of this domain in IRS-2 but not in IRS-1 allows IRS-2 to interact with the insulin receptor independently of the phosphotyrosine-binding domain, and insulin-mediated tyrosine phosphorylation of IRS-2 can be eliminated by interfering with insulin receptor-IRS-2 interaction using a peptide that corresponds to this region (53). Second, IRS-1 but not IRS-2 can modulate insulin receptor tyrosine phosphorylation and activity in response insulin, thereby influencing downstream insulin signaling (54). Third, IRS-1 and 2 differ in their intracellular compartmentalization. In 3T3-L1 adipocytes, IRS-1 is more abundant in intracellular membranes than in the cytosol, whereas IRS-2 is more concentrated in the cytosol, and in response to insulin, the association of phosphatidylinositol 3-kinase with IRS-1 in the intracellular membranes is more stable than with IRS-2 (14). Differences in the time course of action of IRS-1 and IRS-2 also occur, where insulin-stimulated tyrosine phosphorylation of IRS-1 is highly sustained and detectable after 60 min, whereas IRS-2 tyrosine phosphorylation peaks around 3 min and becomes essentially undetectable after 10 min of insulin stimulation (13). Taken together, these distinct characteristics of IRS-1 and IRS-2 as well as their differential insulin sensitivities prompted us to investigate their relative roles in insulin signaling, glucose uptake, and GLUT4 translocation.

As became apparent under "Results" and is discussed further below, the cause-and-effect relationship of IRS-1 or IRS-2 to signaling outcomes does not necessarily adhere to correlations of phosphorylation levels of IRS isoforms and the signals in insulin dose-response curves. Hence, we explored the possible cause-effect relationship upon ablation of each IRS. We report that isoform-specific gene silencing can be achieved by transfecting siRNA into L6 myotubes, with >70% reduction of the targeted protein(s) (Fig. 4). The advantage of this approach is that it achieves transient elimination of specific proteins within a time frame where compensatory up-regulation of alternative signaling pathway is less likely than in gene knockout mice. This system also circumvents the confounding effects of metabolic derangements and organ-to-organ cross-talks that occur in IRS-1- and IRS-2-null mice, which may affect the insulin response independently of the direct IRS effects. We found that a 70% loss of endogenous IRS-1 had only a small effect on activation of ERK (Fig. 6B, upper panel). Similar results have been observed in IRS-1-null 3T3 cells, where activation of ERK1 and ERK2 by IGF-I was normal compared with wild type cells (55). SiRNA-mediated reduction of IRS-2, however, reduced insulin-stimulated ERK phosphorylation by 85% (Fig. 6B, lower panel). These observations suggest that IRS-2 may have a more prominent role in mediating insulin-stimulated mitogenic signaling in L6 myotubes, which occurs largely downstream of ERK.



View larger version (41K):
[in this window]
[in a new window]
  		FIG. 6.
IRS-2 has a greater contribution than IRS-1 to insulin-stimulation of ERK, but both are required for p38MAPK activation. Myotubes were transfected with siRNA targeted specifically against IRS-1, IRS-2, or a siNR. Cells were depleted of serum and insulin for 5 h followed by a 10-min incubation with insulin (0, 5, or 100 nM). Total cell lysates were prepared in Laemmli sample buffer, and 40 µg of protein was immunoblotted for total p38MAPK and phospho-p38MAPK (A) as well as phospho-ERK (B). Results are expressed as a percentage of the response obtained with 100 nM insulin, in cells transfected with siNR, and represent the mean ± S.E. of five to seven independent experiments. *** p < 0.001, ** p < 0.01 and * p < 0.05 versus cells transfected with the siNR at the corresponding insulin concentration. White bars, siNR; striped bars, siIRS-1; black bars, siIRS-2.

 
p38MAPK is activated by insulin (42, 56–58), and dysregulation of p38MAPK activity has been observed in both in vitro models of insulin resistance (34) as well as in adipocytes and muscles from diabetic patients (58, 59). We found that siRNA-mediated reduction of either IRS-1 or IRS-2 significantly tapered insulin-stimulated p38MAPK phosphorylation, with IRS-2 having a slightly more pronounced effect. When both IRS-1 and IRS-2 were reduced, p38MAPK phosphorylation was decreased almost additively (Fig. 9C), suggesting that each IRS isoform contributes separately to this activation. To our knowledge, this is the first demonstration that IRS-1 and IRS-2 are upstream of p38MAPK in insulin signaling.

One of the key findings of this study is that elimination of 75% of IRS-2 did not prevent the full stimulation of glucose uptake by insulin, whereas a comparable elimination of IRS-1 halved the hormonal response of glucose uptake (Fig. 7). These results are consistent with findings in muscles isolated from IRS-1- and IRS-2-null mice (22, 27) (see Table II). In contrast to muscle, in adipose tissues both IRS-1 and IRS-2 seem to be important for the metabolic actions of insulin because isolated primary adipocytes from IRS-1-null mice and brown adipocytes from IRS-2-null mice have impaired insulin-stimulated GLUT4 translocation and glucose uptake (23, 26). These results again highlight the differential regulation of insulin signaling pathways and the importance of examining the function of signaling intermediates in a tissue-specific manner.



View larger version (25K):
[in this window]
[in a new window]
  		FIG. 7.
Differential contribution of IRS-1 versus IRS-2 on insulin-stimulated glucose uptake and GLUT4 translocation in L6 myotubes. 2-Deoxyglucose uptake was measured in myotubes transfected with siNR, siIRS-1 (A), or siIRS-2 (B). Cells were deprived of serum for 5 h and then stimulated with 0, 5, or 100 nM insulin for 20 min followed by a 5-min assay for 2-deoxyglucose uptake. Results are expressed as a percentage of the insulin-stimulated glucose uptake observed with 100 nM insulin in cells transfected with siNR and represent the mean ± S.E. of six to eight independent experiments. Cell surface GLUT4myc was measured in myotubes transfected with siNR, siIRS-1 (A), or siIRS-2 (B), and the results are expressed as a percentage of the cell surface GLUT4 measured in cells transfected with nonrelevant siRNA treated with 100 nM insulin and represent the mean ± S.E. of four independent experiments. *** p < 0.001 and ** p < 0.01 versus cells transfected with siNR at the corresponding insulin concentrations. White bars, siNR; striped bars, siIRS-1; black bars, siIRS-2.

 
Another major result is the differential sensitivity of Akt isoforms to substantial IRS-1 or IRS-2 elimination. Whereas reducing each by about 70% lowered the net insulin-stimulated Akt phosphorylation by 40–50% (Figs. 4 and 5), there was no further loss of Akt phosphorylation upon combined reduction of both IRS isoforms (Fig. 9B). This behavior led us to analyze the response of the two major Akt isoforms, Akt1 and Akt2. This led to the second major observation of this study, that Akt2 is sensitive to reductions in IRS-1 or IRS-2 expression, but only Akt1 is sensitive to a 75% loss of IRS-1. In each case, however, residual Akt-1 or Akt-2 activity remains, revealing that a certain degree of signal amplification occurs through the pathway. Surprisingly, the status of insulin-stimulated Akt phosphorylation in muscles or adipocytes isolated from IRS-1-null mice has never been reported (22, 23). In undifferentiated L6 myoblasts, however, Pirola et al. (43) found that IRS-2 but not IRS-1 is required for the insulin-stimulated increase in Akt phosphorylation. There are two possible explanations for the difference between that study and the present results. First, regulation of insulin signaling pathway may change as myoblasts differentiate into myotubes. Second, Pirola et al. used a 10-fold higher concentration of insulin than we used in this study. It is possible that at this high dose of insulin, activation of Akt occurs through the IGF-I receptor, such that a decrease in insulin-mediated Akt activation through the insulin receptor via IRS-1 would evade detection. In this scenario, the IGF-1 receptor might have signaled via IRS-2.



View larger version (87K):
[in this window]
[in a new window]
  		FIG. 8.
Differential participation of IRS-1 and IRS-2 in insulin-stimulated actin remodeling. Myotubes grown on coverslips were transfected with siIRS-1 (A), siIRS-2 (B), or siNR as described in Fig. 7. Cells were serum deprived for 5 h prior to stimulation with 100 nM insulin for 10 min at 37 °C followed by fixation and permeabilization. Filamentous actin was stained with rhodamine-conjugated phalloidin. The images were acquired from the dorsal surfaces of the myotubes using confocal microscopy and are representative of two independent experiments. White arrowheads indicate remodeled actin structures.

 
The third major observation of this study is that the partial drop in insulin-stimulated Akt phosphorylation (Akt2 isoform) which occurs in siIRS-2-treated cells did not translate into lower insulin-dependent glucose uptake. In contrast, siIRS-1-treated cells displaying similar net reductions in Akt phosphorylation but with reductions in the response of both Akt1 and Akt2 experienced a >50% loss of insulin-stimulated glucose uptake and GLUT4 translocation (Fig. 7). How do we reconcile the impaired Akt phosphorylation in both siIRS-1- and siIRS-2-treated cells with the observation that glucose uptake and the GLUT4 translocation response are only diminished in the siIRS-1-treated cells? First, the residual activated Akt may be sufficient to maintain insulin action in siIRS-2-treated cells, provided that IRS-1 and IRS-2 access different pools of Akt. Although there are no studies to this effect, Akt2 is found predominantly at the plasma membrane whereas Akt1 is largely intracellular (62). Second, it is possible that only when a reduction in Akt-1 compounds the reduction in Akt2, glucose uptake is compromised. These results are consistent with the observation that Akt2-/- Akt1+/- mice are more insulin-resistant than Akt2-/- mice (64). In adipocytes and Chinese hamster ovary cells, both Akt1 and Akt2 participate in insulin-stimulated glucose transport and GLUT4 translocation, although Akt2 plays a more prominent role (32). Third, inputs other than Akt contribute to GLUT4 translocation. Atypical protein kinase Cs have been shown to regulate glucose transport in brown adipocytes from IRS-2-null mice (63). Although not studied here, it is conceivable that the remaining 25% of IRS-2 in the siIRS-2-treated cells is sufficient to activate a protein kinase C and is responsible for the intact insulin-stimulated glucose transport. Finally, and perhaps most relevant, actin remodeling is crucial for GLUT4 translocation but is independent of Akt activity (30). Cortical actin remodeling was impaired when IRS-1 activation was prevented with a blocking peptide in 3T3-L1 adipocytes (18). As shown in Fig. 8, actin remodeling is downstream of IRS-1 but not of IRS-2. Hence, the defect in actin remodeling caused by IRS-1 silencing may compound the concomitant reduction in activation of Akt1 and Akt2, thereby diminishing GLUT4 translocation and glucose uptake. In the case of IRS-2 silencing, the reduction in Akt2 phosphorylation, in the absence of reduction in actin remodeling, may suffice to sustain normal GLUT4 translocation. This scenario is illustrated along with Table II. Whichever the explanation, it is clear that one cannot assume that there is a linear quantitative pathway from IRS to Akt to GLUT4 translocation without influence of other factors.



View larger version (25K):
[in this window]
[in a new window]
  		FIG. 9.
IRS-1 and IRS-2 are not redundant intermediates in the insulin signaling pathways. In A, 2-deoxyglucose uptake was measured in myotubes transfected with siNR or combined siIRS-1 and siIRS-2. Cells were deprived of serum for 5 h, then stimulated with 0, 5, or 100 nM insulin for 20 min followed by a 5-min assay for 2-deoxyglucose uptake. Results are expressed as a percentage of the insulin-stimulated glucose uptake observed at 100 nM insulin in cell transfected with siNR and represent the mean ± S.E. of three independent experiments. Total cell lysates were made from cells transfected with siNR or combined siIRS-1 and siIRS-2 following a 10-min insulin stimulation (5 or 100 nM). 40 µgof protein was immunoblotted for phospho-Ser473-Akt or phospho-Thr308-Akt (B), phospho-p38MAPK (C), and phospho-ERK (D). Results are expressed as a percentage of the response obtained with 100 nM insulin in cells transfected with siNR, and results represent the mean ± S.E. of two or three independent experiments. *** p < 0.001 and ** p < 0.01 versus cells transfected with siNR at the corresponding insulin concentrations. White bars, siNR; gray bars, combined siIRS-1 and siIRS-2.

 
Taken together, our results suggest that in muscle cells, IRS-1 and IRS-2 participate differentially in the mitogenic and metabolic signals of events downstream of Akt, ERK, and p38MAPK. IRS-1 regulates actin remodeling, Akt1 and Akt2 phosphorylation, GLUT4 translocation, and glucose uptake, whereas IRS-2 regulates Akt2 activation but has minimal contribution to these other functions. Conversely, ERK is primarily downstream of IRS-2, and p38MAPK is equally and complementarily activated via IRS-1 and IRS-2. It must be emphasized that because we only eliminated 70% of IRS-2 using siRNA, it remains possible that IRS-2 contributes to glucose uptake in muscle, although it is unlikely to have a profound effect. Future studies aimed to determine the atypical protein kinase C isoform(s) regulated by IRS-1 and IRS-2 will allow us to understand better the molecular basis of their differential impact on metabolic actions of insulin. From a health perspective, the results presented illustrate the differential sensitivity and resilience of distinct signaling pathways to reductions of IRS-1 or IRS-2, which may have implications for patients with variations in this early step in insulin signaling.


   FOOTNOTES
 
* This work was supported in part by Canadian Institutes of Health Research Grant MT-12601 (to A. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

These authors contributed equally to this work. Back

|| Supported by Canadian Institute of Health Research fellowships. Back

** Supported by a Research Institute Training Center fellowship. Back

{ddagger}{ddagger} To whom correspondence should be addressed: The Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, Canada. Tel.: 416-813-6392; Fax: 416-813-5028; E-mail: amira{at}sickkids.ca.

1 The abbreviations used are: IRS, insulin receptor substrate; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; IGF-I, insulin-like growth factor I; {alpha}-MEM, {alpha}-minimum Eagle's medium; siIRS-1, IRS-1-specific siRNA; siIRS-2, IRS-2-specific siRNA; siNR, or nonrelevant siRNA control; siRNA, small interfering RNA. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Phil Bilan for critical appraisal of the data and preparation of this manuscript. We thank Nish Patel and Michelle Levy for assistance in data acquisition.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Goodyear, L. J., Giorgino, F., Sherman, L. A., Carey, J., Smith, R. J., and Dohm, G. L. (1995) J. Clin. Invest. 95, 2195-2204[Medline] [Order article via Infotrieve]
  2. Bjornholm, M., Kawano, Y., Lehtihet, M., and Zierath, J. R. (1997) Diabetes 46, 524-527[Abstract]
  3. Carvalho, E., Jansson, P. A., Axelsen, M., Eriksson, J. W., Huang, X., Groop, L., Rondinone, C., Sjostrom, L., and Smith, U. (1999) FASEB J. 13, 2173-2178[Abstract/Free Full Text]
  4. Krook, A., Bjornholm, M., Galuska, D., Jiang, X. J., Fahlman, R., Myers, M. G., Jr., Wallberg-Henriksson, H., and Zierath, J. R. (2000) Diabetes 49, 284-292[Abstract]
  5. Zierath, J. R., Krook, A., and Wallberg-Henriksson, H. (2000) Diabetologia 43, 821-835[CrossRef][Medline] [Order article via Infotrieve]
  6. White, M. F., Maron, R., and Kahn, C. R. (1985) Nature 318, 183-186[CrossRef][Medline] [Order article via Infotrieve]
  7. White, M. F., and Kahn, C. R. (1994) J. Biol. Chem. 269, 1-4[Free Full Text]
  8. White, M. F. (2002) Am. J. Physiol. 283, H413-E422
  9. Cai, D., Dhe-Paganon, S., Melendez, P. A., Lee, J., and Shoelson, S. E. (2003) J. Biol. Chem. 278, 25323-25330[Abstract/Free Full Text]
  10. Sun, X. J., Wang, L. M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173-177[CrossRef][Medline] [Order article via Infotrieve]
  11. He, W., Craparo, A., Zhu, Y., O'Neill, T. J., Wang, L. M., Pierce, J. H., and Gustafson, T. A. (1996) J. Biol. Chem. 271, 11641-11645[Abstract/Free Full Text]
  12. Sawka-Verhelle, D., Tartare-Deckert, S., White, M. F., and Van Obberghen, E. (1996) J. Biol. Chem. 271, 5980-5983[Abstract/Free Full Text]
  13. Ogihara, T., Shin, B. C., Anai, M., Katagiri, H., Inukai, K., Funaki, M., Fukushima, Y., Ishihara, H., Takata, K., Kikuchi, M., Yazaki, Y., Oka, Y., and Asano, T. (1997) J. Biol. Chem. 272, 12868-12873[Abstract/Free Full Text]
  14. Inoue, G., Cheatham, B., Emkey, R., and Kahn, C. R. (1998) J. Biol. Chem. 273, 11548-11555[Abstract/Free Full Text]
  15. Valverde, A. M., Lorenzo, M., Pons, S., White, M. F., and Benito, M. (1998) Mol. Endocrinol. 12, 688-697[Abstract/Free Full Text]
  16. Quon, M. J., Butte, A. J., Zarnowski, M. J., Sesti, G., Cushman, S. W., and Taylor, S. I. (1994) J. Biol. Chem. 269, 27920-27924[Abstract/Free Full Text]
  17. Rose, D. W., Saltiel, A. R., Majumdar, M., Decker, S. J., and Olefsky, J. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 797-801[Abstract/Free Full Text]
  18. Morris, A. J., Martin, S. S., Haruta, T., Nelson, J. G., Vollenweider, P., Gustafson, T. A., Mueckler, M., Rose, D. W., and Olefsky, J. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8401-8406[Abstract/Free Full Text]
  19. Sharma, P. M., Egawa, K., Gustafson, T. A., Martin, J. L., and Olefsky, J. M. (1997) Mol. Cell. Biol. 17, 7386-7397[Abstract]
  20. Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., and Satoh, S. (1994) Nature 372, 182-186[CrossRef][Medline] [Order article via Infotrieve]
  21. Araki, E., Lipes, M. A., Patti, M. E., Bruning, J. C., Haag, B., III, Johnson, R. S., and Kahn, C. R. (1994) Nature 372, 186-190[CrossRef][Medline] [Order article via Infotrieve]
  22. Yamauchi, T., Tobe, K., Tamemoto, H., Ueki, K., Kaburagi, Y., Yamamoto-Honda, R., Takahashi, Y., Yoshizawa, F., Aizawa, S., Akanuma, Y., Sonenberg, N., Yazaki, Y., and Kadowaki, T. (1996) Mol. Cell. Biol. 16, 3074-3084[Abstract]
  23. Kaburagi, Y., Satoh, S., Tamemoto, H., Yamamoto-Honda, R., Tobe, K., Veki, K., Yamauchi, T., Kono-Sugita, E., Sekihara, H., Aizawa, S., Cushman, S. W., Akanuma, Y., Yazaki, Y., and Kadowaki, T. (1997) J. Biol. Chem. 272, 25839-25844[Abstract/Free Full Text]
  24. Patti, M. E., Sun, X. J., Bruening, J. C., Araki, E., Lipes, M. A., White, M. F., and Kahn, C. R. (1995) J. Biol. Chem. 270, 24670-24673[Abstract/Free Full Text]
  25. Zhou, L., Chen, H., Lin, C. H., Cong, L.-N., McGibbon, M. A., Sciacchitano, S., Lesniak, M. A., Quon, M. J., and Taylor, S. I. (1997) J. Biol. Chem. 272, 29829-29833[Abstract/Free Full Text]
  26. Fasshauer, M., Klein, J., Ueki, K., Kriauciunas, K. M., Benito, M., White, M. F., and Kahn, C. R. (2000) J. Biol. Chem. 275, 25494-25501[Abstract/Free Full Text]
  27. Higaki, Y., Wojtaszewski, J. F., Hirshman, M. F., Withers, D. J., Towery, H., White, M. F., and Goodyear, L. J. (1999) J. Biol. Chem. 274, 20791-20795[Abstract/Free Full Text]
  28. Previs, S. F., Withers, D. J., Ren, J.-M., White, M. F., and Shulman, G. I. (2000) J. Biol. Chem. 275, 38990-38994[Abstract/Free Full Text]
  29. Tsakiridis, T., Vranic, M., and Klip, A. (1994) J. Biol. Chem. 269, 29934-29942[Abstract/Free Full Text]
  30. Wang, Q., Somwar, R., Bilan, P. J., Liu, Z., Jin, J., Woodgett, J. R., and Klip, A. (1999) Mol. Cell. Biol. 19, 4008-4018[Abstract/Free Full Text]
  31. Tong, P., Khayat, Z. A., Huang, C., Patel, N., Ueyama, A., and Klip, A. (2001) J. Clin. Invest. 108, 371-381[CrossRef][Medline] [Order article via Infotrieve]
  32. Jiang, Z. Y., Zhou, Q. L., Coleman, K. A., Chouinard, M., Boese, Q., and Czech, M. P. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 7569-7574[Abstract/Free Full Text]
  33. Katome, T., Obata, T., Matsushima, R., Masuyama, N., Cantley, L. C., Gotoh, Y., Kishi, K., Shiota, H., and Ebina, Y. (2003) J. Biol. Chem. 278, 28312-28323[Abstract/Free Full Text]
  34. Huang, C., Somwar, R., Patel, N., Niu, W., Torok, D., and Klip, A. (2002) Diabetes 51, 2090-2098[Abstract/Free Full Text]
  35. Wang, Q., Khayat, Z., Kishi, K., Ebina, Y., and Klip, A. (1998) FEBS Lett. 427, 193-197[CrossRef][Medline] [Order article via Infotrieve]
  36. Ueyama, A., Yaworsky, K. L., Wang, Q., Ebina, Y., and Klip, A. (1999) Am. J. Physiol. 277, E572-E578
  37. Kanai, F., Nishioka, Y., Hayashi, H., Kamohara, S., Todaka, M., and Ebina, Y. (1993) J. Biol. Chem. 268, 14523-14526[Abstract/Free Full Text]
  38. Li, D., Randhawa, V. K., Patel, N., Hayashi, M., and Klip, A. (2001) J. Biol. Chem. 276, 22883-22891[Abstract/Free Full Text]
  39. Patel, N., Rudich, A., Khayat, Z. A., Garg, R., and Klip, A. (2003) Mol. Cell. Biol. 23, 4611-4626[Abstract/Free Full Text]
  40. Somwar, R., Sweeney, G., Ramlal, T., and Klip, A. (1998) Clin. Ther. 20, 125-140[CrossRef][Medline] [Order article via Infotrieve]
  41. JeBailey, L., Rudich, A., Huang, X., Di Ciano-Oliveira, C., Kapus, A., and Klip, A. (2004) Mol. Endocrinol. 18, 359-372[Abstract/Free Full Text]
  42. Sweeney, G., Somwar, R., Ramlal, T., Volchuk, A., Ueyama, A., and Klip, A. (1999) J. Biol. Chem. 274, 10071-10078[Abstract/Free Full Text]
  43. Pirola, L., Bonnafous, S., Johnston, A. M., Chaussade, C., Portis, F., and Van Obberghen, E. (2003) J. Biol. Chem. 278, 15641-15651[Abstract/Free Full Text]
  44. Niu, W., Huang, C., Nawaz, Z., Levy, M., Somwar, R., Li, D., Bilan, P. J., and Klip, A. (2003) J. Biol. Chem. 278, 17953-17962[Abstract/Free Full Text]
  45. Khayat, Z. A., Tong, P., Yaworsky, K., Bloch, R. J., and Klip, A. (2000) J. Cell Sci. 113, 279-290[Abstract]
  46. Omata, W., Shibata, H., Li, L., Takata, K., and Kojima, I. (2000) Biochem. J. 346, 321-328
  47. Kanzaki, M., and Pessin, J. E. (2001) J. Biol. Chem. 276, 42436-42444[Abstract/Free Full Text]
  48. Brozinick, J. T., Hawkins, E. D., Strawbridge, A. B., and Elmendorf, J. S. (2004) J. Biol. Chem. 279, 40699-40706[Abstract/Free Full Text]
  49. Miele, C., Caruso, M., Calleja, V., Auricchio, R., Oriente, F., Formisano, P., Condorelli, G., Cafieri, A., Sawka-Verhelle, D., Van Obberghen, E., and Beguinot, F. (1999) J. Biol. Chem. 274, 3094-3102[Abstract/Free Full Text]
  50. Leibiger, B., Leibiger, I. B., Moede, T., Kemper, S., Kulkarni, R. N., Kahn, C. R., de Vargas, L. M., and Berggren, P. O. (2001) Mol. Cell 7, 559-570[CrossRef][Medline] [Order article via Infotrieve]
  51. Sesti, G., Federici, M., Lauro, D., Sbraccia, P., and Lauro, R. (2001) Diabetes-Metab. Res. Rev. 17, 363-373[CrossRef][Medline] [Order article via Infotrieve]
  52. Sciacca, L., Prisco, M., Wu, A., Belfiore, A., Vigneri, R., and Baserga, R. (2003) Endocrinology 144, 2650-2658[Abstract/Free Full Text]
  53. Oriente, F., Formisano, P., Miele, C., Fiory, F., Maitan, M. A., Vigliotta, G., Trencia, A., Santopietro, S., Caruso, M., Van Obberghen, E., and Beguinot, F. (2001) J. Biol. Chem. 276, 37109-37119[Abstract/Free Full Text]
  54. Solow, B. T., Harada, S., Goldstein, B. J., Smith, J. A., White, M. F., and Jarett, L. (1999) Mol. Endocrinol. 13, 1784-1798[Abstract/Free Full Text]
  55. Bruning, J. C., Winnay, J., Cheatham, B., and Kahn, C. R. (1997) Mol. Cell. Biol. 17, 1513-1521[Abstract]
  56. Somwar, R., Perreault, M., Kapur, S., Taha, C., Sweeney, G., Ramlal, T., Kim, D. Y., Keen, J., Cote, C. H., Klip, A., and Marette, A. (2000) Diabetes 49, 1794-1800[Abstract]
  57. Bazuine, M., Ouwens, D. M., Gomes de Mesquita, D. S., and Maassen, J. A. (2003) Eur. J. Biochem. 270, 3891-3903[Medline] [Order article via Infotrieve]
  58. Leng, Y., Steiler, T. L., and Zierath, J. R. (2004) Diabetes 53, 1436-1444[Abstract/Free Full Text]
  59. Carlson, C. J., Koterski, S., Sciotti, R. J., Poccard, G. B., and Rondinone, C. M. (2003) Diabetes 52, 634-641[Abstract/Free Full Text]
  60. Deleted in proof
  61. Deleted in proof
  62. Sasaoka, T., Wada, T., Fukui, K., Murakami, S., Ishihara, H., Suzuki, R., Tobe, K., Kadowaki, T., and Kobayashi, M. (2004) J. Biol. Chem. 279, 14835-14843[Abstract/Free Full Text]
  63. Arribas, M., Valverde, A. M., Burks, D., Klein, J., Farese, R. V., White, M. F., and Benito, M. (2003) FEBS Lett. 536, 161-166[CrossRef][Medline] [Order article via Infotrieve]
  64. Bae, S. S., Cho, H., Mu, J., and Birnbaum, M. J. (2003) J. Biol. Chem. 278, 49530-49536[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. R. White, L. D. Martin, M. K. Abe, B. A. Marroquin, R. Stern, and X. Fu
Insulin receptor substrate-1/2 mediates IL-4-induced migration of human airway epithelial cells
Am J Physiol Lung Cell Mol Physiol, July 1, 2009; 297(1): L164 - L173.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Sasaki-Suzuki, K. Arai, T. Ogata, K. Kasahara, H. Sakoda, K. Chida, T. Asano, J. E. Pessin, F. Hakuno, and S.-I. Takahashi
Growth Hormone Inhibition of Glucose Uptake in Adipocytes Occurs without Affecting GLUT4 Translocation through an Insulin Receptor Substrate-2-Phosphatidylinositol 3-Kinase-dependent Pathway
J. Biol. Chem., March 6, 2009; 284(10): 6061 - 6070.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
S. Hanke and M. Mann
The Phosphotyrosine Interactome of the Insulin Receptor Family and Its Substrates IRS-1 and IRS-2
Mol. Cell. Proteomics, March 1, 2009; 8(3): 519 - 534.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. L. Pankratz, E. Y. Tan, Y. Fine, A. M. Mercurio, and L. M. Shaw
Insulin Receptor Substrate-2 Regulates Aerobic Glycolysis in Mouse Mammary Tumor Cells via Glucose Transporter 1
J. Biol. Chem., January 23, 2009; 284(4): 2031 - 2037.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
G. J. Francis, J. A. Martinez, W. Q. Liu, K. Xu, A. Ayer, J. Fine, U. I. Tuor, G. Glazner, L. R. Hanson, W. H. Frey II, et al.
Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy
Brain, December 1, 2008; 131(12): 3311 - 3334.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Roher, V. Samokhvalov, M. Diaz, S. MacKenzie, A. Klip, and J. V. Planas
The Proinflammatory Cytokine Tumor Necrosis Factor-{alpha} Increases the Amount of Glucose Transporter-4 at the Surface of Muscle Cells Independently of Changes in Interleukin-6
Endocrinology, April 1, 2008; 149(4): 1880 - 1889.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
M. Lorenzo, S. Fernandez-Veledo, R. Vila-Bedmar, L. Garcia-Guerra, C. De Alvaro, and I. Nieto-Vazquez
Insulin resistance induced by tumor necrosis factor-{alpha} in myocytes and brown adipocytes
J Anim Sci, April 1, 2008; 86(14_suppl): E94 - E104.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Perrini, A. Natalicchio, L. Laviola, A. Cignarelli, M. Melchiorre, F. De Stefano, C. Caccioppoli, A. Leonardini, S. Martemucci, G. Belsanti, et al.
Abnormalities of Insulin-Like Growth Factor-I Signaling and Impaired Cell Proliferation in Osteoblasts from Subjects with Osteoporosis
Endocrinology, March 1, 2008; 149(3): 1302 - 1313.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H. Sharfi and H. Eldar-Finkelman
Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling
Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E307 - E315.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Hakuno, S. Kurihara, R. T. Watson, J. E. Pessin, and S.-I. Takahashi
53BP2S, Interacting with Insulin Receptor Substrates, Modulates Insulin Signaling
J. Biol. Chem., December 28, 2007; 282(52): 37747 - 37758.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Diaz, C. N. Antonescu, E. Capilla, A. Klip, and J. V. Planas
Fish Glucose Transporter (GLUT)-4 Differs from Rat GLUT4 in Its Traffic Characteristics but Can Translocate to the Cell Surface in Response to Insulin in Skeletal Muscle Cells
Endocrinology, November 1, 2007; 148(11): 5248 - 5257.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. A. Frost and C. H. Lang
Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass
J Appl Physiol, July 1, 2007; 103(1): 378 - 387.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
G. F. Anhe, S. M. Hirabara, T. C. Turrer, L. C. Caperuto, F. F. Anhe, L. M. Ribeiro, A. C. Marcal, C. R. O. Carvalho, R. Curi, U. F. Machado, et al.
Postpartum glycemic homeostasis in early lactating rats is accompanied by transient and specific increase of soleus insulin response through IRS2/AKT pathway
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2007; 292(6): R2225 - R2233.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
D. Huang, M. Khoe, M. Befekadu, S. Chung, Y. Takata, D. Ilic, and M. Bryer-Ash
Focal adhesion kinase mediates cell survival via NF-{kappa}B and ERK signaling pathways
Am J Physiol Cell Physiol, April 1, 2007; 292(4): C1339 - C1352.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Jager, T. Gremeaux, M. Cormont, Y. Le Marchand-Brustel, and J.-F. Tanti
Interleukin-1{beta}-Induced Insulin Resistance in Adipocytes through Down-Regulation of Insulin Receptor Substrate-1 Expression
Endocrinology, January 1, 2007; 148(1): 241 - 251.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Wei, J. R. Sowers, R. Nistala, H. Gong, G. M.-E. Uptergrove, S. E. Clark, E. M. Morris, N. Szary, C. Manrique, and C. S. Stump
Angiotensin II-induced NADPH Oxidase Activation Impairs Insulin Signaling in Skeletal Muscle Cells
J. Biol. Chem., November 17, 2006; 281(46): 35137 - 35146.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. P. Sajan, J. Rivas, P. Li, M. L. Standaert, and R. V. Farese
Repletion of Atypical Protein Kinase C following RNA Interference-mediated Depletion Restores Insulin-stimulated Glucose Transport
J. Biol. Chem., June 23, 2006; 281(25): 17466 - 17473.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. M. Rondinone
Minireview: Ribonucleic Acid Interference for the Identification of New Targets for the Treatment of Metabolic Diseases
Endocrinology, June 1, 2006; 147(6): 2650 - 2656.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Wijesekara, A. Tung, F. Thong, and A. Klip
Muscle cell depolarization induces a gain in surface GLUT4 via reduced endocytosis independently of AMPK
Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1276 - E1286.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. L. Bailey, B. Zheng, Z. Hu, S. R. Price, and W. E. Mitch
Chronic Kidney Disease Causes Defects in Signaling through the Insulin Receptor Substrate/Phosphatidylinositol 3-Kinase/Akt Pathway: Implications for Muscle Atrophy
J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1388 - 1394.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. C.P. Thirone, L. JeBailey, P. J. Bilan, and A. Klip
Opposite Effect of JAK2 on Insulin-Dependent Activation of Mitogen-Activated Protein Kinases and Akt in Muscle Cells: Possible Target to Ameliorate Insulin Resistance.
Diabetes, April 1, 2006; 55(4): 942 - 951.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Weigert, A. M. Hennige, T. Brischmann, A. Beck, K. Moeschel, M. Schauble, K. Brodbeck, H.-U. Haring, E. D. Schleicher, and R. Lehmann
The Phosphorylation of Ser318 of Insulin Receptor Substrate 1 Is Not per se Inhibitory in Skeletal Muscle Cells but Is Necessary to Trigger the Attenuation of the Insulin-stimulated Signal
J. Biol. Chem., November 11, 2005; 280(45): 37393 - 37399.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. Plomgaard, K. Bouzakri, R. Krogh-Madsen, B. Mittendorfer, J. R. Zierath, and B. K. Pedersen
Tumor Necrosis Factor-{alpha} Induces Skeletal Muscle Insulin Resistance in Healthy Human Subjects via Inhibition of Akt Substrate 160 Phosphorylation
Diabetes, October 1, 2005; 54(10): 2939 - 2945.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
F. S. L. Thong, C. B. Dugani, and A. Klip
Turning Signals On and Off: GLUT4 Traffic in the Insulin-Signaling Highway
Physiology, August 1, 2005; 20(4): 271 - 284.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/19/19426    most recent
M412317200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, C.
Right arrow Articles by Klip, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, C.
Right arrow Articles by Klip, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement